Rho Experts Explore Right-to-Try Legislation and Existing Expanded Access Programs in Free Webinar
WHAT: The impact of Right-to-Try legislation has been in the news a lot recently, but what does the legislation mean for product sponsors? Rho, a full-service contract research organization (CRO), will explore both Right-to-Try legislation and existing Expanded Access Programs in a new free webinar, including:
- Understanding sponsor responsibilities under these programs and when products may be eligible
- Evaluating options such as treatment protocols, treatment INDs, and emergency use
- Discussing development risks associated with participation in these programs
The webinar, “Right-to-Try or Right-to-Ask? Understanding Right-to-Try and FDA’s Expanded Access,” will take place on Tuesday, Dec. 11 from 1-2 p.m. EST.
The presenters will also discuss several examples from their personal experience as well as noteworthy examples that have made the news.
WHO: David Shoemaker, Ph.D., senior vice president, R&D, Rho
WHEN: Tuesday, Dec. 11, 2018
WHERE: Register to attend this free webinar at this link.
DETAILS: For media inquiries, please contact Jordan Lockhart at Largemouth Communications, 919-459-6461,firstname.lastname@example.org.
ABOUT: Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 35 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter.